Leslie Casias
Acute Care · Seattle, WANPI 1699085308
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,084 of the $60,241 with a category attached, or 79.8%. AbbVie accounts for 81.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $21,840 and has fallen 95.7% since, to $932 in 2025. Among acute care clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $207.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$49K
- Biohaven Pharmaceuticals, Inc.$7K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Impel Pharmaceuticals Inc.$517
- Teva Pharmaceuticals USA, Inc.$275
- Merz North America, Inc.$224
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$48,08480%
- Travel & lodging$6,00510%
- Food & beverage$6,14110%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 159 | $48,872 |
| Biohaven Pharmaceuticals, Inc. | 27 | $6,711 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $2,272 |
| Impel Pharmaceuticals Inc. | 16 | $517 |
| Teva Pharmaceuticals USA, Inc. | 19 | $275 |
| Merz North America, Inc. | 4 | $224 |
| Pfizer | 7 | $216 |
| Lilly USA, LLC | 5 | $177 |
| Amgen | 11 | $166 |
| Lundbeck LLC | 6 | $155 |
| Tonix Medicines, Inc. | 1 | $139 |
| Merz Pharmaceuticals, LLC | 4 | $138 |
| Upsher-smith Laboratories LLC | 5 | $120 |
| Supernus Pharmaceuticals, Inc. | 5 | $111 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Ipsen Biopharmaceuticals, Inc | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Acorda Therapeutics, Inc | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$44,066
- QULIPTA$16,496
- NURTEC ODT$8,266
- Trudhesa$217
- ZEMBRACE SYMTOUCH$139
- TOSYMRA$139
- BOTOX$121
How this compares
$60,241 in reported general payments places this provider in the 95th percentile of 135 acute care providers in Washington.
Other acute care in Seattle
- Jennifer HartleySeattle$121K
- Elizabeth PerpetuaSeattle$112K
- Joelle FathiSeattle$22K
- Sirithepphavanh OliverSeattle$19K
- Desiree WoodSeattle$4K
- Sarah LivesaySeattle$3K
- Kathryn KeurianSeattle$1K
- Elizabeth SieberSeattle$1K
- Elmira Jangi KhatounabadSeattle$646
- Lisa GuertinSeattle$504
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.